Axcella Health
| General Information | |
| Business: | We are a biotechnology company pioneering the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Our AXA Candidates are generated from our proprietary, human-focused AXA Development Platform and harness the power of endogenous metabolic modulators, or EMMs, a broad family of molecules that fundamentally impact and regulate human metabolism.  | 
                        
| Industry: | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) | 
| Employees: | 49 | 
| Founded: | 2008 | 
| Contact Information | |
| Address | 840 Memorial Drive, Cambridge, MA 02139, US | 
| Phone Number | (857) 320-2200 | 
| Web Address | https://www.axcellahealth.com. | 
| View Prospectus: | Axcella Health | 
| Financial Information | |
| Market Cap | $459.8mil | 
| Revenues | $0 mil (last 12 months) | 
| Net Income | $-36.1 mil (last 12 months) | 
| IPO Profile | |
| Symbol | AXLA | 
| Exchange | NASDAQ | 
| Shares (millions): | 3.6 | 
| Price range | $20.00 - $20.00 | 
| Est. $ Volume | $71.4 mil | 
| Manager / Joint Managers | Goldman Sachs/ J.P. Morgan/ SVB Leerink | 
| CO-Managers | - | 
| Expected To Trade: | 5/9/2019 | 
| Status: | Priced | 
| Quiet Period Expiration Date: | Available only to Subscribers | 
| Lock-Up Period Expiration Date: | Available only to Subscribers | 
| SCOOP Rating | Available only to Subscribers | 
| Rating Change | Available only to Subscribers |